Successful provision of CAR-T therapy during a pandemic: low SARS-CoV-2 infection rates and reduction in ICU admissions following modification of patient pathway.
Autorzy:
Carter-Brzezinski L; Department of Clinical Haematology, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, UK. Davies E; Department of Clinical Haematology, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, UK. Norman J; Department of Clinical Haematology, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, UK. Rubio L; Department of Clinical Haematology, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, UK. Dixon C; Department of Critical Care Medicine, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, UK. Brett S; Department of Clinical Haematology, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, UK. DunneT; Department of Critical Care Medicine, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, UK. Iqbal S; Department of Clinical Haematology, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, UK. Dignan FL; Department of Clinical Haematology, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, UK. Ahmad S; Department of Virology, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, UK. Machin N; Department of Virology, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, UK. Morriss H; Department of Critical Care Medicine, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, UK. Wilson A; Department of Critical Care Medicine, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, UK. Tholouli E; Department of Clinical Haematology, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, UK.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2022 Dec; Vol. 63 (13), pp. 3265-3267. Date of Electronic Publication: 2022 Aug 22.
Excess of deaths for patients with plasma cell proliferative disorders as a result of the COVID-19 pandemic.
Autorzy:
DunneT; Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, Canada. Stewart D; Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, Canada. Lee H; Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, Canada. Tay J; Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, Canada. Duggan P; Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, Canada. McCulloch S; Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, Canada. Neri P; Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, Canada.; Charbonneau Cancer Research Institute, Calgary, Canada. Bahlis NJ; Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, Canada.; Charbonneau Cancer Research Institute, Calgary, Canada. Jimenez-Zepeda VH; Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, Canada.; Charbonneau Cancer Research Institute, Calgary, Canada.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2021 Dec; Vol. 62 (14), pp. 3555-3557. Date of Electronic Publication: 2021 Aug 26.
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies
